AbbVie’s Skyrizi Poised To Enter Packed Psoriasis Market
AbbVie’s Skyrizi Poised To Enter Packed Psoriasis Market
$200.00
AbbeVie is banking on the success of a possible simultaneous European/US launch of Skyrizi, its psoriasis drug, to bolster the company’s declining revenues in Europe. Read about how the company plans to use Skyrizi to bounce back from the genericization of its blockbuster Humira in this informative article.
Author: Kevin Grogan
Publisher: Scrip
- Description
As AbbeVie faces the off-patent realities of its blockbuster Humira, the company is gearing up for the launch of Skyrizi (risankizumab), its interleukin-23 inhibitor psoriasis drug. The drug has gained a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), and if US FDA grants its approval, the company will launch Skyrizi almost simultaneously in Europe and the US. Discover more here about the progress of a Skyrizi launch and what it means for AbbeVie.
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Novartis Can’t Halt Janssen’s Promo Comparing Their Psoriasis Drugs 
Sign up to the